Skip navigation

Partnerships

The importance of alliances and partnerships

At Biogen Idec, our mission is to address serious, unmet medical needs through innovative and effective therapies. We pursue that mission any way we can. So, while we are proud of our ability to develop treatments through our own internal R&D, we are equally committed to alliances and partnerships.

Our approach to partnerships reflects the same dedication to innovation seen everywhere in the company. We are flexible enough to structure a partnership in any way that makes sense for both companies. And we offer the ideal blend of large (broad resources) and small (personal attention).

We work with companies at all stages in the development process, from proof-of-concept to Phase 3 testing and beyond.

We welcome the opportunity to discuss a partnership arrangement or alliance with any appropriate organization.

The ability to strengthen our pipeline through partnerships has been and will continue to be an important driver of Biogen Idec's growth.

Jim Mullen
President and CEO, Biogen Idec

Alliances that work

Many of our products, both current and in the pipeline, are a result of alliances and collaborations. We have collaborated more than once with many of our partners, proof of the success of these relationships. Among our partners:

Acorda
AVEO Pharmaceuticals, Inc.
Alnylam Pharmaceuticals
Bayer Schering Pharma
Caprion Pharmaceuticals, Inc.
Cardiokine
Dyas
Elan
Escoublac, Inc.
Fumapharm AG
Genentech
Mondobiotech
Neurimmune Therapies AG
Neostasis
NsGene A/S
Provasculon, Inc.
Sunesis
UCB S.A., Ltd.
Vernalis, plc
Zenyaku Kogyo Co., Ltd.